CRIS Connect: Fostering Collaborations to Advance Clinical Research and Therapeutic Development
Registration
Please register via https://for.sg/crisconnect
Registration closes Thu, 26 Feb 2026.
About the Speakers
A/Prof Melvin Chua
Head and Senior Consultant
Department of Head and Neck and Thoracic Cancers, National Cancer Centre Singapore (NCCS)
A/Prof Melvin Chua is a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. He is currently an Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; Visiting Professor of the Zhongnan Hospital of Wuhan University, China. He is also a Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP).
Additionally, he is the Department Head and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, and Director of the Data and Computational Science Hub at the NCCS. A/Prof Chua has published over 230 peer-reviewed papers, with a H-index of 48 (>13,000 citations); He is the Lead Author of the Nasopharynx Cancer Chapter of the 12th edition of the Cancer: Principles & Practice of Oncology – the most widely-used oncology textbook worldwide, as well as other highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology.
Consequently, he is listed as the World’s Top 2% Most Cited Scientists in consecutive years from 2023 to 2025. For his work, he has received numerous honours, including the SingHealth Excellence Distinguished Researcher Award, Conquer Cancer Foundation ASCO Merit Awards, NMRC Clinician-Scientist Award (Investigator), Fellow of the Royal College of Radiologists, Fellow of the Academy of Medicine Singapore (FAMS), and Fellow of the American Society of Clinical Oncology (FASCO; first Singaporean National to be inducted for class of 2025).
Dr Robin Chan
Scientific Director
Singapore Translational Cancer Consortium (STCC), Consortium for Clinical Research and Innovation, Singapore (CRIS)
As the Scentific Director of Singapore Translational Cancer Consortium (STCC), Dr Robin Chan oversees the development and coordination of collaborative, investigator-led cancer research across Singapore’s public healthcare and academic institutions. His work involves strengthening translational research platforms, supporting investigator-initiated studies, and fostering strategic partnerships that bridge healthcare institutions, academia, and industry.
Dr Chan received his PhD in Biochemistry and completed his academic training at the National University of Singapore and Columbia University Medical Center. He has over 15 years of experience spanning academic research and the biotechnology industry, with expertise in multi-omics analysis and translational biology in neurodegeneration, infectious diseases and oncology.
Prior to joining STCC, he held senior scientific and strategic roles in biotechnology, where he led the development of multi-omics research platforms and cross-institutional academic–industry collaborations.